The FDA has approved the CytoCell KMT2A Breakapart FISH Probe Kit PDx as a companion diagnostic (CDx) to accompany revumenib (Revuforj), a first-in-class Menin inhibitor for the treatment of relapsed ...

Findings suggest bispecific CD3xCD20 therapy may offer an option for patients with Richter syndrome who are ineligible for ...

The McDonald criteria revisions provide a unified approach for diagnosing MS from pediatric to late-life presentations, said ...

Multiple sclerosis (MS) could be "on the brink of a new class of treatment" after early trial results suggest two drugs may repair damage caused by the condition.

Some older adults with MS on disease-modifying therapies, mainly patients 60 and older, may be able to discontinue DMTs if ...

MS causes the body to attack myelin, the protective membrane around nerve cells, causing debilitating symptoms such as ...

Almost half of women with MS remain untreated during family planning, though ocrelizumab is the most commonly used DMT in this population.

New research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis ...

The 2024 McDonald criteria improve early MS diagnosis with higher sensitivity and accuracy, but lower specificity in real-world settings.